MétaCan
Menu
Retour à la cohorte
Enregistrement W2940847506 · doi:10.1097/01.ju.0000557133.04919.da

MP72-01 IMPROVEMENTS IN FREEDOM FROM PROGRESSION WITH SHORT TERM ANDROGEN DEPRIVATION THERAPY AND PELVIC LYMPH NODE TREATMENT ADDED TO PROSTATE BED SALVAGE RADIOTHERAPY: THE NRG ONCOLOGY/RTOG 0534 SPPORT TRIAL

2019· article· en· W2940847506 sur OpenAlexaboutno aff
Alan Pollack, Theodore Karrison, Alexander G. Balogh, Daniel A. Low, Deborah Watkins Bruner, Jeffrey S. Wefel, Leonard G. Gomella, André‐Guy Martin, Jeff M. Michalski, Steve Angyalfi, Himansu Lukka, Sergio Faria, George Rodrigues, Marie-Claude Beauchemin, R. Jeffrey Lee, Samantha A. Seaward, Aaron M. Allen, Petah Tikva, Drew C. Monitto, Wendy Seiferheld, Howard M. Sandler

Notice bibliographique

RevueThe Journal of Urology · 2019
Typearticle
Langueen
DomainePhysics and Astronomy
ThématiqueAdvanced Radiotherapy Techniques
Établissements canadiensnon disponible
Organismes subventionnairesnon disponible
Mots-clésMedicineAndrogen deprivation therapyProstate cancerOncologyLymph nodeSalvage therapyRadiation therapyInternal medicineUrologyChemotherapyCancer

Résumé

récupéré en direct d'OpenAlex

You have accessJournal of UrologyProstate Cancer: Localized: Radiation Therapy (MP72)1 Apr 2019MP72-01 IMPROVEMENTS IN FREEDOM FROM PROGRESSION WITH SHORT TERM ANDROGEN DEPRIVATION THERAPY AND PELVIC LYMPH NODE TREATMENT ADDED TO PROSTATE BED SALVAGE RADIOTHERAPY: THE NRG ONCOLOGY/RTOG 0534 SPPORT TRIAL Alan Pollack, Theodore Karrison, Alexander G. Balogh, Daniel Low, Deborah W. Bruner, Jeffrey S. Wefel, PhD Leonard G. Gomella*, André-Guy Martin, Jeff M. Michalski, Steve J. Angyalfi, Himansu Lukka, Sergio L. Faria, George B. Rodrigues, Marie-Claude Beauchemin, R. Jeffrey Lee, Samantha A. Seaward, Aaron M. Allen, Petah Tikva, Drew C. Monitto, Wendy Seiferheld, and Howard M. Sandler Alan PollackAlan Pollack More articles by this author , Theodore KarrisonTheodore Karrison More articles by this author , Alexander G. BaloghAlexander G. Balogh More articles by this author , Daniel LowDaniel Low More articles by this author , Deborah W. BrunerDeborah W. Bruner More articles by this author , Jeffrey S. WefelJeffrey S. Wefel More articles by this author , Leonard G. Gomella*Leonard G. Gomella* More articles by this author , André-Guy MartinAndré-Guy Martin More articles by this author , Jeff M. MichalskiJeff M. Michalski More articles by this author , Steve J. AngyalfiSteve J. Angyalfi More articles by this author , Himansu LukkaHimansu Lukka More articles by this author , Sergio L. FariaSergio L. Faria More articles by this author , George B. RodriguesGeorge B. Rodrigues More articles by this author , Marie-Claude BeaucheminMarie-Claude Beauchemin More articles by this author , R. Jeffrey LeeR. Jeffrey Lee More articles by this author , Samantha A. SeawardSamantha A. Seaward More articles by this author , Aaron M. AllenAaron M. Allen More articles by this author , Petah TikvaPetah Tikva More articles by this author , Drew C. MonittoDrew C. Monitto More articles by this author , Wendy SeiferheldWendy Seiferheld More articles by this author , and Howard M. SandlerHoward M. Sandler More articles by this author View All Author Informationhttps://doi.org/10.1097/01.JU.0000557133.04919.daAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVES: Salvage prostate bed radiotherapy (PBRT) results in about 70% 5 yr freedom from progression (FFP). A three arm randomized trial was designed to determine whether there are incremental gains in FFP by adding (i) 4-6 mo of short term androgen deprivation therapy (STAD) to PBRT and (ii) the combination of STAD and pelvic lymph node treatment (PLNRT) to PBRT. METHODS: Patients were randomized to PBRT alone (Arm 1), PBRT + STAD (Arm 2), and PLNRT + PBRT + STAD (Arm 3). The FFP primary endpoint included PSA nadir+2, clinical failure, or death from any cause. The sample size provided 90% power to detect a 10% absolute FFP improvement at 5 yr in Arm 2 compared to Arm 1 and another 10% improvement in Arm 3 compared to Arm 2 (overall alpha of 0.025). Based on 1191 eligible patents with 5 yr minimum follow-up on the third planned interim analysis for efficacy and futility, stepwise comparisons were made to determine if the Haybittle-Peto (HP) threshold boundary of p < 0.001 (one sided) was crossed. Futility evaluation tested the alternative hypotheses at p < 0.001. Adverse events were graded using CTCAEv3.0. RESULTS: From 2008-2015, 1792 patients were enrolled. Of these, 1736 were eligible with a median age of 64 yr, black in 13%, baseline Zubrod status of 0 in 93%, seminal vesicle involvement in 15%, pre-radiotherapy PSA of ≤1.0 ng/ml in 89%, Gleason score <8 in 83%, and pT2 margin positive or pT3 in 72%. Median follow-up for those living is 5.4 yr. For the 1191 patients in the interim analysis cohort, the 5 yr FFP rates for Arms 1, 2, and 3 were 71%, 83% and 89%. When compared to Arm 1, Arm 3 exceeded the HP boundary with a hazard ratio (HR) 0.44 (95% CI: 0.32-0.59). Arm 3 was then compared to Arm 2, yielding a difference of 6% (p = 0.0063) and an HR of 0.71 (95% CI: 0.51-0.98). In all eligible patients followed for up to 8 years, there were 45, 38 and 25 patients who developed distant metastasis (DM) in Arms 1, 2 and 3. The HR was 0.52 (95% CI: 0.32-0.85) for Arm 3 vs Arm 1 and 0.64 (95% CI: 0.39-1.06) for Arm 3 vs. Arm 2. With IMRT use in 87% of cases, there were no significant differences in late grade 2+ or 3+ renal/GU or GI events; only grade 2+ blood/bone marrow events attributable to PLNRT were significant (p<0.044). CONCLUSIONS: These are the first randomized findings to demonstrate that extending salvage radiotherapy to cover the pelvic lymph nodes results in early, meaningful, reductions in progression when combined with STAD. Follow-up of patients will further elucidate the magnitude of the differences in DM and in FFP between arms 2 and 3. Source of Funding: This project was supported by grants U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC), UG1CA189867 (NCORP), U24CA180803 (IROC) from the National Cancer Institute (NCI) Miami, FL; Philadelphia, PA; Calgary, Canada; Los Angeles, CA; Atlanta, GA; Houston, TX; Philadelphia, PA; Quebec, Canada; St. Louis, MO; Calgary, Canada; Hamilton Ontario, Canada; Montreal, Canada; London, Canada; Montreal, Canada; Riverton, UT; Oakland, CA; Israel; Spartanburg, SC; Philadelphia, PA; Los Angeles, CA© 2019 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 201Issue Supplement 4April 2019Page: e1054-e1055 Advertisement Copyright & Permissions© 2019 by American Urological Association Education and Research, Inc.MetricsAuthor Information Alan Pollack More articles by this author Theodore Karrison More articles by this author Alexander G. Balogh More articles by this author Daniel Low More articles by this author Deborah W. Bruner More articles by this author Jeffrey S. Wefel More articles by this author Leonard G. Gomella* More articles by this author André-Guy Martin More articles by this author Jeff M. Michalski More articles by this author Steve J. Angyalfi More articles by this author Himansu Lukka More articles by this author Sergio L. Faria More articles by this author George B. Rodrigues More articles by this author Marie-Claude Beauchemin More articles by this author R. Jeffrey Lee More articles by this author Samantha A. Seaward More articles by this author Aaron M. Allen More articles by this author Petah Tikva More articles by this author Drew C. Monitto More articles by this author Wendy Seiferheld More articles by this author Howard M. Sandler More articles by this author Expand All Advertisement PDF downloadLoading ...

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction machine sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.

score de la tête « metaresearch » (Codex)0,001
score de la tête « metaresearch » (Gemma)0,002
Version: metacan-v3-hybrid-931329e0061cStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Essai non randomisé · Signal consensuel: aucune
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,012
Score d'incertitude au seuil0,039

Scores du classifieur distillé par catégorie (deux têtes)

CatégorieCodexGemma
Métarecherche0,0010,002
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0010,001
Bibliométrie0,0000,000
Études des sciences et des technologies0,0000,000
Communication savante0,0010,001
Science ouverte0,0000,000
Intégrité de la recherche0,0010,003
Charge utile insuffisante (le modèle a refusé de juger)0,0120,001

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,012
Tête enseignante GPT0,294
Écart entre enseignants0,281 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeEssai non randomisé
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations2
Publié2019
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueThe Journal of UrologyMême sujetAdvanced Radiotherapy TechniquesTravaux en français237 207